Holen Sie sich die Stockscreener-App
9.69
7.80%
-0.82
Handel nachbörslich:
9.69
Schlusskurs vom Vortag:
$10.51
Offen:
$10.17
24-Stunden-Volumen:
1.49M
Relative Volume:
1.86
Marktkapitalisierung:
$760.83M
Einnahmen:
$54.55M
Nettoeinkommen (Verlust:
$-193.57M
KGV:
-3.3529
EPS:
-2.89
Netto-Cashflow:
$-181.86M
1W Leistung:
-20.25%
1M Leistung:
-32.05%
6M Leistung:
-56.35%
1J Leistung:
-30.49%
1-Tages-Spanne:
$9.45
$10.52
1-Wochen-Bereich:
$9.45
$12.03
52-Wochen-Spanne:
$9.45
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Vergleichen Sie NRIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
9.69 | 760.83M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 4.2%What's Next? - MarketBeat
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program - MSN
Nurix Therapeutics (NASDAQ:NRIX) Given "Buy" Rating at HC Wainwright - MarketBeat
NEOS Investment Management LLC Takes $425,000 Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.9%Should You Sell? - MarketBeat
Nurix expands licensing deal with Sanofi - The Pharma Letter
Nurix Therapeutics (NRIX) Projected to Post Earnings on Wednesday - MarketBeat
Nurix Therapeutics (NRIX) Surges After Licensing Deal with Sanof - GuruFocus
Sanofi licensing deal boosts Nurix shares - MSN
Nurix stock rises after Sanofi licensing deal (NRIX:NASDAQ) - Seeking Alpha
Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 Analysts - Benzinga
Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program - MarketScreener
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases - The Manila Times
Major Pharma Deal: Nurix's AI Platform Lands $480M Potential Sanofi Partnership - Stock Titan
Trend Tracker for (NRIX) - news.stocktradersdaily.com
Nurix Therapeutics (NASDAQ:NRIX) Hits New 12-Month LowWhat's Next? - MarketBeat
Nurix Therapeutics Inc (NASDAQ: NRIX) Drops -2.22%, Turning Investors Away - stocksregister.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Verastem (NASDAQ:VSTM) versus Nurix Therapeutics (NASDAQ:NRIX) Head-To-Head Analysis - Defense World
Proficio Capital Partners LLC Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Position Boosted by Charles Schwab Investment Management Inc. - MarketBeat
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting - The Manila Times
Nurix Therapeutics Announces Multiple Presentations At The American Association For Cancer Research (AACR) 2025 Annual Meeting - MarketScreener
Revolutionary AI Platform Drives 4 Cancer Drug Innovations: Nurix AACR 2025 Spotlight - Stock Titan
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 6.2%Here's What Happened - MarketBeat
Primecap Management Co. CA Sells 58,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Q3 Earnings Estimate for NRIX Issued By Leerink Partnrs - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Raised to "Hold" at Leerink Partnrs - MarketBeat
Victory Capital Management Inc. Buys 38,672 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Q1 Earnings Estimate for NRIX Issued By Leerink Partnrs - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 4.4%Should You Buy? - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely - simplywall.st
Nikko Asset Management Americas Inc. Acquires 236,620 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Analysts at Leerink Partners - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Upgraded at Leerink Partnrs - Defense World
Victory Capital Management Inc. Increases Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 6.9%What's Next? - MarketBeat
Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock - Benzinga
Nurix Therapeutics gets 'market perform' rating as Leerink starts coverage - TradingView
Leerink Partners Initiates Coverage of Nurix Therapeutics (NRIX) with Market Perform Recommendation - Nasdaq
Nurix Therapeutics' Bexobrutideg Gets Orphan Drug Designation For Waldenstrm Macroglobulinemia - Nasdaq
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):